Although non-steroidal anti-inflammatory drugs (NSAIDs) were not therapeutic for AD, it is possible that more selective blockers of the innate immune system might be effective in AD and/or DS, for example, through inhibition of the TLR2-MyD88 interaction or of JAK-1 (Rangasamy et al., 2018; Rachubinski et al., 2019; Tuttle et al., 2020). Here, JAK1 is linked to Alzheimer disease.